Influence of Immersion Period on the Corrosion Behavior of Heat Treated Biomedical Alloy Ti -5Al - 2.5Fe

Heat treatment by solid solution method in the ?+? phase region was used at 970°C for Ti-5Al-2.5Fe alloy. The specimens cooled under different cooling media [water quenched (WQ), air cooled (AC) and furnace cooled (FC)], and subsequently aged at 550°C for 4 hours. Five specimens from each treatment were immersed in simulated body fluid SBF for a period of time (3 months). The dependence of corrosion rate on compositional variation in the phases resulted from various type of cooling rates are discussed based on immersion tests. The EDXA results show the precipitation of phosphate and calcium compounds on the alloy after 3 months of immersion in blood plasma solution forming a bone-like apatite, which enhanced the alloy biocompatibility making it more suitable to use as biomedical implant

Synthesis of I@MPA-Mn:ZnSe as an efficient contrast agent for CT/ fluorescence bi-modal imaging application

Bi-modal imaging contrast agent has attracted considerable attention in medical physics research field via quantum dots (QDs) fabrications. Doped quantum dots are playing an important role in seeking alternatives to conventional heavy metal-containing particles for medical applications. In order to improve imaging diagnosis, herein we report the design and synthesis of I@MPA-Mn:ZnSe as an efficient contrast agent. The medium, mercaptopropionic acid (MPA) capped Mn:ZnSe QDs surface-conjugated with a commercial contrast agent (Iohexol), was synthesized in seeking to overcome the limitations of Iohexol, also towards advancing bi-modal imaging approaches. In this study, morphology, elemental, absorption and fluorescence analysis were investigated, followed by a preliminary study of CT contrast enhancement and cell viability. In comparison to Iohexol, the fluorescence of I@MPA-Mn:ZnSe is observed at 585 nm. The CT Hounsfield unit (HU) increases linearly with mass concentration, with a four-fold increment in HU over that of Iohexol, producing greater than 328 ΔHU at similar concentrations, confirming the CT contrast efficiency of I@MPA-Mn:ZnSe. Cytotoxicity studies have confirmed that the medium possesses good biocompatibility and low toxicity to cells (HepG2 and MDA-MB-321). Present results for CT enhancement and brightness of fluorescence of I@MPA-Mn:ZnSe point to its great potential as a bi-modal contrast medium for further diagnosis applications

Analysis of human ES cell differentiation establishes that the dominant isoforms of the lncRNAs RMST and FIRRE are circular

Abstract Background Circular RNAs (circRNAs) are predominantly derived from protein coding genes, and some can act as microRNA sponges or transcriptional regulators. Changes in circRNA levels have been identified during human development which may be functionally important, but lineage-specific analyses are currently lacking. To address this, we performed RNAseq analysis of human embryonic stem (ES) cells differentiated for 90 days towards 3D laminated retina. Results A transcriptome-wide increase in circRNA expression, size, and exon count was observed, with circRNA levels reaching a plateau by day 45. Parallel statistical analyses, controlling for sample and locus specific effects, identified 239 circRNAs with expression changes distinct from the transcriptome-wide pattern, but these all also increased in abundance over time. Surprisingly, circRNAs derived from long non-coding RNAs (lncRNAs) were found to account for a significantly larger proportion of transcripts from their loci of origin than circRNAs from coding genes. The most abundant, circRMST:E12-E6, showed a > 100X increase during differentiation accompanied by an isoform switch, and accounts for > 99% of RMST transcripts in many adult tissues. The second most abundant, circFIRRE:E10-E5, accounts for > 98% of FIRRE transcripts in differentiating human ES cells, and is one of 39 FIRRE circRNAs, many of which include multiple unannotated exons. Conclusions Our results suggest that during human ES cell differentiation, changes in circRNA levels are primarily globally controlled. They also suggest that RMST and FIRRE, genes with established roles in neurogenesis and topological organisation of chromosomal domains respectively, are processed as circular lncRNAs with only minor linear species

Umweltfreundliche Stueckverzinkung Schlussbericht

Available from TIB Hannover: FR 5978+a / FIZ - Fachinformationszzentrum Karlsruhe / TIB - Technische InformationsbibliothekSIGLEDEGerman

Inhibitory role of Annexin A1 in pathological bone resorption and therapeutic implications in periprosthetic osteolysis

Periprosthetic osteolysis is a cause of arthroplasty failure without available therapies. Here the authors show that Annexin A1 (AnxA1) is involved in in periprosthetic osteolysis and exerts potential therapeutic effects through suppressing NF kappa B signaling and promoting the PPAR-gamma pathway resulting in inhibition of inflammation and osteoclasts differentiation induced by wear debris. There is currently no therapy available for periprosthetic osteolysis, the most common cause of arthroplasty failure. Here, the role of AnxA1 in periprosthetic osteolysis and potential therapeutics were investigated. Reducing the expression of AnxA1 in calvarial tissue was found to be associated with increased osteolytic lesions and the osteolytic lesions induced by debris implantation were more severe in AnxA1-defecient mice than in wild-type mice. AnxA1 inhibits the differentiation of osteoclasts through suppressing NF kappa B signaling and promoting the PPAR-gamma pathway. Administration of N-terminal-AnxA1 (Ac2-26 peptide) onto calvariae significantly reduced osteolytic lesions triggered by wear debris. These therapeutic effects were abrogated in mice that had received the PPAR-gamma antagonist, suggesting that the AnxA1/PPAR-gamma axis has an inhibitory role in osteolysis. The administration of Ac2-26 suppressed osteolysis induced by TNF-alpha and RANKL injections in mice. These findings indicate that AnxA1 is a potential therapeutic agent for the treatment of periprosthetic osteolysis